Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial

Table 4 Comparison of hematological toxicity between chemoradiotherapy and chemotherapy reported in major clinically trials of GC

Study (Ref.), Year	Cancer type	Treatment group and HT
ARTIST Trial (4), 2004	GC, Adjuvant therapy, pTNM stage II–III, with node-positive	XP (n = 226) XP-RT (n = 227)
ARTIST Trial (4), 2004	GC, Adjuvant therapy, pTNM stage II–III, with node-positive	Grade 3 + neutropenia 40.7% 48.4% Grade 3 + anemia 1.7% 0.4% Grade 3 + thrombocytopenia 0 0.9%
CRITICS Trial (24), 2007	GC and EGJC, Adjuvant therapy, pTNM stage IB–IVA	ChT (n = 233) CRT (n = 245)
CRITICS Trial (24), 2007	GC and EGJC, Adjuvant therapy, pTNM stage IB–IVA	Grade 3 + leukopenia <1.0% 1.0% Grade 3 + neutropenia 27.0% 4.4% Grade 3 + thrombocytopenia <1.0% 1.3%
TOPGEAR Trial interim results (8), 2009	GC, Neoadjuvant therapy, cTNM stage IB–IIIC	ECF/ECX (n = 60) ECF/ECX-RT (n = 60)
TOPGEAR Trial interim results (8), 2009	GC, Neoadjuvant therapy, cTNM stage IB–IIIC	Grade 3 + neutropenia 40.0% 45.0% Grade 3 + anemia 7.0% 5.0% Grade 3 + thrombocytopenia 3.0% 2.0% Grade 3 + total HTs 50.0% 52.0%
ARTIS-2 Trial (5), 2013	GC, Adjuvant therapy, pTNM stage II–III, with node-positive	S-1 (n = 182) SOX (n = 180) SOX-RT (n = 181)
ARTIS-2 Trial (5), 2013	GC, Adjuvant therapy, pTNM stage II–III, with node-positive	Grade 3 + neutropenia 1.0% 3.0% 3.0% Grade 3 + anemia 5.0% 8.0% 7.0% Grade 3 + thrombocytopenia 0 3.0% 0

EGJC, esophagogastric junction cancer; XP, capecitabine and cisplatin; RT, radiotherapy; ChT, chemotherapy; CRT, chemoradiotherapy; ECF, epirubicin, cisplatin, and 5-fluorouracil; ECX, epirubicin, cisplatin, and capecitabine; SOX, S-1 and oxaliplatin

ISSN: 1748-717X